APA (7th ed.) Citation

A, P., J, O., J, M., P, H., D, M., E, V., . . . M, H. (2023). Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age. Vaccines, 11(10), . https://doi.org/10.3390/vaccines11101528

Chicago Style (17th ed.) Citation

A, Poder, Oberije J, Meyer J, Heymer P, Molrine D, Versage E, Isakov L, Zhang Q, and Hohenboken M. "Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age." Vaccines 11, no. 10 (2023). https://doi.org/10.3390/vaccines11101528.

MLA (9th ed.) Citation

A, Poder, et al. "Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age." Vaccines, vol. 11, no. 10, 2023, https://doi.org/10.3390/vaccines11101528.